{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:36:51Z","timestamp":1781455011784,"version":"3.54.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00296-017-3775-5","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T09:19:24Z","timestamp":1501147164000},"page":"25-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Biological therapies for the treatment of Beh\u00e7et\u2019s disease-related uveitis beyond TNF-alpha blockade: a narrative review"],"prefix":"10.1007","volume":"38","author":[{"given":"Jurgen","family":"Sota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"3775_CR1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12016-012-8319-x","volume":"43","author":"H Yazici","year":"2012","unstructured":"Yazici H, Ugurlu S, Seyahi E (2012) Beh\u00e7et syndrome: is it one condition? Clin Rev Allergy Immunol 43:275\u2013280","journal-title":"Clin Rev Allergy Immunol"},{"key":"3775_CR2","first-page":"1","volume":"14","author":"D Rigante","year":"2010","unstructured":"Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14:1\u201318","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4 Suppl 60","key":"3775_CR3","first-page":"S2","volume":"28","author":"H Beh\u00e7et","year":"2010","unstructured":"Beh\u00e7et H, Matteson EL (2010) On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus-1937. Clin Exp Rheumatol 28(4 Suppl 60):S2\u2013S5","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60\u201376","journal-title":"Medicine (Baltimore)"},{"key":"3775_CR5","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"3775_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3627-4","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G et al (2017) Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease. Clin Rheumatol. doi:\n                        10.1007\/s10067-017-3627-4","journal-title":"Clin Rheumatol"},{"key":"3775_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183\u2013189. doi:\n                        10.1007\/s10067-016-3480-x","journal-title":"Clin Rheumatol"},{"key":"3775_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G et al (2017) Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451\u2013455. doi:\n                        10.1007\/s10067-016-3417-4","journal-title":"Clin Rheumatol"},{"issue":"785\u201396","key":"3775_CR9","first-page":"e3","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(785\u201396):e3","journal-title":"Ophthalmology"},{"issue":"6 Suppl 94","key":"3775_CR10","first-page":"S141","volume":"33","author":"M Accorinti","year":"2015","unstructured":"Accorinti M, Pesci FR, Pirraglia MP, Priori R, Pivetti-Pezzi P (2015) Multi-drug resistance and side-effects in a patient with Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 33(6 Suppl 94):S141\u2013S144","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"C Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Beh\u00e7et disease responsive to anakinra. Ann Intern Med 149:284\u2013286","journal-title":"Ann Intern Med"},{"issue":"4 Suppl 84","key":"3775_CR12","first-page":"S172","volume":"32","author":"G Emmi","year":"2014","unstructured":"Emmi G, Silvestri E, Ciucciarelli L, Squatrito D, Emmi L (2014) Reply: anti-IL1 blocking agents in drug-resistant Beh\u00e7et\u2019s syndrome: our little case series. Clin Exp Rheumatol 32(4 Suppl 84):S172","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR13","first-page":"152","volume":"31","author":"G Emmi","year":"2013","unstructured":"Emmi G, Silvestri E, Cameli AM et al (2013) Anakinra for resistant Beh\u00e7et uveitis: why not? Clin Exp Rheumatol 31:152\u2013153","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P et al (2015) Anakinra treatment in drug-resistant Beh\u00e7et\u2019s disease: a case series. Clin Rheumatol 34:1293\u20131301","journal-title":"Clin Rheumatol"},{"issue":"3 Suppl 72","key":"3775_CR15","first-page":"S115","volume":"30","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 30(3 Suppl 72):S115","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/rheumatology\/kev197","volume":"54","author":"I Pagnini","year":"2015","unstructured":"Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R (2015) Successful treatment with canakinumab of a paediatric patient with resistant Beh\u00e7et\u2019s disease. Rheumatology (Oxford) 54:1327\u20131328","journal-title":"Rheumatology (Oxford)"},{"key":"3775_CR17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA et al (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et\u2019s disease: an open-label pilot study. Ann Rheum Dis 71:563\u2013566","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 84","key":"3775_CR18","first-page":"S171","volume":"32","author":"F Caso","year":"2014","unstructured":"Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) Efficacy of anakinra in refractory Beh\u00e7et\u2019s disease sacroiliitis. Clin Exp Rheumatol 32(4 Suppl 84):S171","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology 228:211\u2013214","journal-title":"Dermatology"},{"key":"3775_CR20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Beh\u00e7et\u2019s syndrome with refractory eye disease. Ann Rheum Dis 71:1589\u20131591","journal-title":"Ann Rheum Dis"},{"key":"3775_CR21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12026-013-8411-1","volume":"56","author":"F Caso","year":"2013","unstructured":"Caso F, Iaccarino L, Bettio S et al (2013) Refractory pemphigus foliaceus and Beh\u00e7et\u2019s disease successfully treated with tocilizumab. Immunol Res 56:390\u2013397","journal-title":"Immunol Res"},{"issue":"Suppl 102","key":"3775_CR22","first-page":"34","volume":"34","author":"M Santos-G\u00f3mez","year":"2016","unstructured":"Santos-G\u00f3mez M, Calvo-R\u00edo V, Blanco R et al (2016) The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol 34(Suppl 102):34\u201340","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 84","key":"3775_CR23","first-page":"S54","volume":"32","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, de la Hera D, Beltr\u00e1n-Catal\u00e1n E et al (2014) Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32(4 Suppl 84):S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.semarthrit.2016.03.006","volume":"46","author":"G Emmi","year":"2016","unstructured":"Emmi G, Silvestri E, Squatrito D, Emmi L, Cantarini L, Prisco D (2016) Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Beh\u00e7et\u05f3s disease. Semin Arthritis Rheum 46:e1\u2013e2","journal-title":"Semin Arthritis Rheum"},{"key":"3775_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e318284735c","volume":"19","author":"E Perez-Pampin","year":"2013","unstructured":"Perez-Pampin E, Campos-Franco J, Blanco J, Mera A (2013) Remission induction in a case of refractory Beh\u00e7et disease with alemtuzumab. J Clin Rheumatol 19:101\u2013103","journal-title":"J Clin Rheumatol"},{"key":"3775_CR26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","volume":"45","author":"A Deroux","year":"2016","unstructured":"Deroux A, Chiquet C, Bouillet L (2016) Tocilizumab in severe and refractory Beh\u00e7et\u2019s disease: four cases and literature review. Semin Arthritis Rheum 45:733\u2013737","journal-title":"Semin Arthritis Rheum"},{"key":"3775_CR27","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","volume":"262","author":"DP Kidd","year":"2015","unstructured":"Kidd DP (2015) Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et\u2019s syndrome. J Neurol 262:2676\u20132677","journal-title":"J Neurol"},{"key":"3775_CR28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","volume":"20","author":"M Khairallah","year":"2012","unstructured":"Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH (2012) Epidemiology of Beh\u00e7et disease. Ocul Immunol Inflamm 20:324\u2013335","journal-title":"Ocul Immunol Inflamm"},{"key":"3775_CR29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1755-3768.1992.tb04888.x","volume":"70","author":"M Soylu","year":"1992","unstructured":"Soylu M, Ers\u00f6z TR, Erken E (1992) The association between HLA B5 and ocular involvement in Beh\u00e7et\u2019s disease in southern Turkey. Acta Ophthalmol (Copenhagen) 70:786\u2013789","journal-title":"Acta Ophthalmol (Copenhagen)"},{"key":"3775_CR30","first-page":"653539","volume":"2014","author":"UC Park","year":"2014","unstructured":"Park UC, Kim TW, Yu HG (2014) Immunopathogenesis of ocular Beh\u00e7et\u2019s disease. J Immunol Res 2014:653539","journal-title":"J Immunol Res"},{"key":"3775_CR31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/jir.2010.0148","volume":"31","author":"H Belguendouz","year":"2011","unstructured":"Belguendouz H, Messaoud\u00e8ne D, Lahmar K et al (2011) Interferon-\u03b3 and nitric oxide production during Beh\u00e7et uveitis: immunomodulatory effect of interleukin-10. J Interferon Cytokine Res 31:643\u2013651","journal-title":"J Interferon Cytokine Res"},{"key":"3775_CR32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu HG, Chung H (2006) Intraocular cytokine environment in active Beh\u00e7et uveitis. Am J Ophthalmol 142:429\u2013434","journal-title":"Am J Ophthalmol"},{"key":"3775_CR33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1006\/bbrc.2002.6487","volume":"291","author":"J Yamaoka","year":"2002","unstructured":"Yamaoka J, Kabashima K, Kawanishi M, Toda K, Miyachi Y (2002) Cytotoxicity of IFN-gamma and TNF-alpha for vascular endothelial cell is mediated by nitric oxide. Biochem Biophys Res Commun 291:780\u2013786","journal-title":"Biochem Biophys Res Commun"},{"key":"3775_CR34","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.4049\/jimmunol.172.3.1588","volume":"172","author":"E Roth","year":"2004","unstructured":"Roth E, Pircher H (2004) IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. J Immunol 172:1588\u20131594","journal-title":"J Immunol"},{"key":"3775_CR35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2249.2004.02536.x","volume":"137","author":"HG Yu","year":"2004","unstructured":"Yu HG, Lee DS, Seo JM et al (2004) The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Beh\u00e7et\u2019s uveitis. Clin Exp Immunol 137:437\u2013443","journal-title":"Clin Exp Immunol"},{"key":"3775_CR36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","volume":"11","author":"M Pineton de Chambrun","year":"2012","unstructured":"Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Beh\u00e7et\u2019s disease. Autoimmun Rev 11:687\u2013698","journal-title":"Autoimmun Rev"},{"key":"3775_CR37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2559.2000.00859.x","volume":"6","author":"M Kobayashi","year":"2000","unstructured":"Kobayashi M, Ito M, Nakagawa A et al (2000) Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Beh\u00e7et disease. Histopathology 6:362\u2013371","journal-title":"Histopathology"},{"key":"3775_CR38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","volume":"25","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 25:469\u2013484","journal-title":"Semin Immunol"},{"key":"3775_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-003-0400-6","volume":"25","author":"N D\u00fczg\u00fcn","year":"2005","unstructured":"D\u00fczg\u00fcn N, Aya\u015flio\u011flu E, Tutkak H, Aydintu\u011f OT (2005) Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Beh\u00e7et\u2019s disease. Rheumatol Int 25:1\u20135","journal-title":"Rheumatol Int"},{"key":"3775_CR40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00296-005-0040-0","volume":"26","author":"S Pay","year":"2006","unstructured":"Pay S, Erdem H, Pekel A et al (2006) Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Beh\u00e7et\u2019s disease. Does interleukin-1 beta play a major role in Beh\u00e7et\u2019s synovitis? Rheumatol Int 26:608\u2013613","journal-title":"Rheumatol Int"},{"key":"3775_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","volume":"29","author":"Y Bilginer","year":"2010","unstructured":"Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Beh\u00e7et\u2019s disease. Clin Rheumatol 29:209\u2013210","journal-title":"Clin Rheumatol"},{"key":"3775_CR42","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G et al (2016) Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol 35:1281\u20131286","journal-title":"Clin Rheumatol"},{"key":"3775_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13337","author":"G Emmi","year":"2016","unstructured":"Emmi G, Silvestri E, Squatrito D et al (2016) Long-term efficacy and safety of anakinra in a patient with Beh\u00e7et\u2019s disease and concomitant tuberculosis infection. Int J Dermatol. doi:\n                        10.1111\/ijd.13337\n                        \n                     (Epub ahead of print)","journal-title":"Int J Dermatol"},{"key":"3775_CR44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:191\u2013197","journal-title":"Clin Rheumatol"},{"issue":"7","key":"3775_CR45","first-page":"380","volume":"24","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol 24(7):380","journal-title":"Front Pharmacol"},{"key":"3775_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease. Autoimmun Rev 14:1\u20139","journal-title":"Autoimmun Rev"},{"key":"3775_CR47","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295. doi:\n                        10.1101\/cshperspect.a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3775_CR48","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. Eur J Immunol 40:1830\u20131835","journal-title":"Eur J Immunol"},{"key":"3775_CR49","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1126\/science.1083901","volume":"300","author":"MJ Boulanger","year":"2003","unstructured":"Boulanger MJ, Chow DC, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex. Science 300:2101\u20132104","journal-title":"Science"},{"key":"3775_CR50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","volume":"387","author":"T Naka","year":"1997","unstructured":"Naka T, Narazaki M, Hirata M et al (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924\u2013929","journal-title":"Nature"},{"key":"3775_CR51","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","volume":"48","author":"T Yoshimura","year":"2009","unstructured":"Yoshimura T, Sonoda KH, Ohguro N et al (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 48:347\u2013354","journal-title":"Rheumatology (Oxford)"},{"key":"3775_CR52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","volume":"31","author":"K Hamzaoui","year":"2002","unstructured":"Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Beh\u00e7et\u2019s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205\u2013210","journal-title":"Scand J Rheumatol"},{"key":"3775_CR53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","volume":"22","author":"T Hirano","year":"2012","unstructured":"Hirano T, Ohguro N, Hohki S et al (2012) A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22:298\u2013302","journal-title":"Mod Rheumatol"},{"key":"3775_CR54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","volume":"114","author":"LS Shapiro","year":"2012","unstructured":"Shapiro LS, Farrell J, Borhani Haghighi A (2012) Tocilizumab treatment for neuro-Beh\u00e7et\u2019s disease, the first report. Clin Neurol Neurosurg 114:297\u2013298","journal-title":"Clin Neurol Neurosurg"},{"key":"3775_CR55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/0886022X.2013.773913","volume":"35","author":"MD Redondo-Pach\u00f3n","year":"2013","unstructured":"Redondo-Pach\u00f3n MD, Enr\u00edquez R, Sirvent AE et al (2013) Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Beh\u00e7et\u2019s disease. Ren Fail 35:547\u2013550","journal-title":"Ren Fail"},{"key":"3775_CR56","first-page":"S75","volume":"32","author":"M Papo","year":"2014","unstructured":"Papo M, Bielefeld P, Vallet H et al (2014) Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 32:S75\u2013S79","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR57","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","volume":"52","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hatemi G (2013) Lack of efficacy of tocilizumab in mucocutaneous Behcet\u2019s syndrome: report of two cases. Rheumatology (Oxford) 52:1923\u20131924","journal-title":"Rheumatology (Oxford)"},{"key":"3775_CR58","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Vitale A et al (2015) Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab. Clin Rheumatol 34:1141\u20131143","journal-title":"Clin Rheumatol"},{"key":"3775_CR59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/1547691X.2012.707700","volume":"10","author":"EG Lee","year":"2013","unstructured":"Lee EG, Mickle-Kawar BM, Gallucci RM (2013) IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis. J Immunotoxicol 10:192\u2013200","journal-title":"J Immunotoxicol"},{"key":"3775_CR60","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/rheumatology\/kev255","volume":"54","author":"W Terreaux","year":"2015","unstructured":"Terreaux W, Mestrallet S, Fauconier M et al (2015) Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm. Rheumatology (Oxford) 54:2111\u20132113","journal-title":"Rheumatology (Oxford)"},{"key":"3775_CR61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120:777\u2013787","journal-title":"Ophthalmology"},{"key":"3775_CR62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaci.2011.07.008","volume":"128","author":"H Direskeneli","year":"2011","unstructured":"Direskeneli H, Fujita H, Akdis CA (2011) Regulation of TH17 and regulatory T cells in patients with Beh\u00e7et disease. J Allergy Clin Immunol 128:665\u2013666","journal-title":"J Allergy Clin Immunol"},{"key":"3775_CR63","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"G Geri","year":"2011","unstructured":"Geri G, Terrier B, Rosenzwajg M et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease. J Allergy Clin Immunol 128:655\u2013664","journal-title":"J Allergy Clin Immunol"},{"key":"3775_CR64","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1167\/iovs.07-1390","volume":"49","author":"W Chi","year":"2008","unstructured":"Chi W, Zhu X, Yang P et al (2008) Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis. Invest Ophthalmol Vis Sci 49:3058\u20133064","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3775_CR65","first-page":"S16","volume":"28","author":"J Kim","year":"2010","unstructured":"Kim J, Park JA, Lee EY, Lee YJ, Song YW, Lee EB (2010) Imbalance of Th17 to Th1 cells in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 28:S16\u2013S19","journal-title":"Clin Exp Rheumatol"},{"key":"3775_CR66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M, McKeage K (2015) Secukinumab: first global approval. Drugs 75:329\u2013338","journal-title":"Drugs"},{"key":"3775_CR67","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.4049\/jimmunol.179.10.7128","volume":"179","author":"Y Yamaguchi","year":"2007","unstructured":"Yamaguchi Y, Fujio K, Shoda H et al (2007) IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol 179:7128\u20137136","journal-title":"J Immunol"},{"key":"3775_CR68","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","volume":"35","author":"SH Chang","year":"2011","unstructured":"Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35:611\u2013621","journal-title":"Immunity"},{"key":"3775_CR69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233\u2013240","journal-title":"J Exp Med"},{"key":"3775_CR70","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A et al (2009) Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633\u2013640","journal-title":"Lancet"},{"key":"3775_CR71","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","volume":"72","author":"EM Baerveldt","year":"2013","unstructured":"Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP (2013) Successful long-term triple disease control by ustekinumab in a patient with Beh\u00e7et\u2019s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 72:626\u2013627","journal-title":"Ann Rheum Dis"},{"key":"3775_CR72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","volume":"15","author":"RR Buggage","year":"2007","unstructured":"Buggage RR, Levy-Clarke G, Sen HN et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm 15:63\u201370","journal-title":"Ocul Immunol Inflamm"},{"key":"3775_CR73","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/bcp.13051","volume":"82","author":"L Diao","year":"2016","unstructured":"Diao L, Hang Y, Othman AA et al (2016) Population PK-PD analyses of CD25 occupancy, CD56 (bright) NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. Br J Clin Pharmacol 82:1333\u20131342","journal-title":"Br J Clin Pharmacol"},{"key":"3775_CR74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, T\u00fcrk\u00f6z Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm 11:87\u201393","journal-title":"Mediat Inflamm"},{"key":"3775_CR75","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/iji.12039","volume":"40","author":"A Y\u00fccel","year":"2013","unstructured":"Y\u00fccel A, Dilek K, Saba D, Oz\u00e7imen AA, Yurtkuran M, Oral HB (2013) Interleukin-2 gene polymorphism in Turkish patients with Beh\u00e7et\u2019s disease and its association with ocular involvement. Int J Immunogenet 40:349\u2013355","journal-title":"Int J Immunogenet"},{"key":"3775_CR76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcjo.2011.06.008","volume":"46","author":"K Wroblewski","year":"2011","unstructured":"Wroblewski K, Sen HN, Yeh S et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 46:322\u2013328","journal-title":"Can J Ophthalmol"},{"issue":"802\u201312","key":"3775_CR77","first-page":"e1","volume":"146","author":"JH Kempen","year":"2008","unstructured":"Kempen JH, Gangaputra S, Daniel E et al (2008) Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146(802\u201312):e1","journal-title":"Am J Ophthalmol"},{"key":"3775_CR78","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-012-0694-x","volume":"23","author":"TA Gheita","year":"2013","unstructured":"Gheita TA, Raafat H, Khalil H, Hussein H (2013) Serum level of APRIL\/BLyS in Beh\u00e7et\u2019s disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol 23:542\u2013546","journal-title":"Mod Rheumatol"},{"key":"3775_CR79","doi-asserted-by":"crossref","first-page":"380405","DOI":"10.1155\/2014\/380405","volume":"2014","author":"OG Shaker","year":"2014","unstructured":"Shaker OG, Tawfic SO, El-Tawdy AM, El-Komy MH, El Menyawi M, Heikal AA (2014) Expression of TNF-\u03b1, APRIL and BCMA in Beh\u00e7et\u2019s disease. J Immunol Res 2014:380405","journal-title":"J Immunol Res"},{"key":"3775_CR80","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1529-0131(200107)44:7<1707::AID-ART295>3.0.CO;2-P","volume":"44","author":"CH Suh","year":"2001","unstructured":"Suh CH, Park YB, Song J, Lee CH, Lee SK (2001) Oligoclonal B lymphocyte expansion in the synovium of a patient with Beh\u00e7et\u2019s disease. Arthritis Rheum 44:1707\u20131712","journal-title":"Arthritis Rheum"},{"key":"3775_CR81","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","volume":"18","author":"S Sadreddini","year":"2008","unstructured":"Sadreddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Beh\u00e7et\u2019s disease with rituximab. Mod Rheumatol 18:306\u2013308","journal-title":"Mod Rheumatol"},{"key":"3775_CR82","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10067-013-2433-x","volume":"33","author":"BH Zhao","year":"2014","unstructured":"Zhao BH, Oswald AE (2014) Improved clinical control of a challenging case of Beh\u00e7et\u2019s disease with rituximab therapy. Clin Rheumatol 33:149\u2013150","journal-title":"Clin Rheumatol"},{"key":"3775_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204366","author":"MJ Messina","year":"2014","unstructured":"Messina MJ, Rodegher M, Scotti R, Martinelli V (2014) Treatment of myelitis in Beh\u00e7et\u2019s disease with rituximab. BMJ Case Rep. doi:\n                        10.1136\/bcr-2014-204366","journal-title":"BMJ Case Rep"},{"key":"3775_CR84","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in intractable ocular lesions of Beh\u00e7et\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246\u2013252","journal-title":"Int J Rheum Dis"},{"key":"3775_CR85","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s10067-014-2781-1","volume":"34","author":"F Caso","year":"2015","unstructured":"Caso F, Rigante D, Vitale A et al (2015) Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt\u2013Koyanagi\u2013Harada disease. Clin Rheumatol 34:1817\u20131820","journal-title":"Clin Rheumatol"},{"key":"3775_CR86","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth SG (2015) Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 16:16414\u201316439","journal-title":"Int J Mol Sci"},{"key":"3775_CR87","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42:1539\u20131544","journal-title":"Rheumatology (Oxford)"},{"key":"3775_CR88","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","volume":"42","author":"AJ Mohammad","year":"2015","unstructured":"Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR (2015) Alemtuzumab as remission induction therapy in Beh\u00e7et disease: a 20-year experience. J Rheumatol 42:1906\u20131913","journal-title":"J Rheumatol"},{"key":"3775_CR89","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","volume":"6","author":"AD Kirk","year":"2006","unstructured":"Kirk AD, Hale DA, Swanson SJ, Mannon RB (2006) Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 6:1084\u20131085","journal-title":"Am J Transplant"},{"key":"3775_CR90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","volume":"99","author":"GH Daniels","year":"2014","unstructured":"Daniels GH, Vladic A, Brinar V et al (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80\u201389","journal-title":"J Clin Endocrinol Metab"},{"key":"3775_CR91","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12016-014-8455-6","volume":"49","author":"S Schwartzman","year":"2015","unstructured":"Schwartzman S, Schwartzman M (2015) The use of biologic therapies in uveitis. Clin Rev Allergy Immunol 49:307\u2013316","journal-title":"Clin Rev Allergy Immunol"},{"key":"3775_CR92","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","volume":"36","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Sota J et al (2017) IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol 36:1459\u20131469","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3775-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T07:05:50Z","timestamp":1515481550000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3775-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3775"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3775-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}